Expert recommendations for the prevention of common respiratory viral infections in neonates

Neonatal Health Care Committee of Chinese Maternal and Child Health Association

doi:10.7499/j.issn.1008-8830.2405078

PDF(581 KB)

Chinese Journal of Contemporary Pediatrics ›› 2024, Vol. 26 ›› Issue (8) : 789-794. DOI: 10.7499/j.issn.1008-8830.2405078

STANDARD·PROTOCOL·GUIDELINE

Expert recommendations for the prevention of common respiratory viral infections in neonates

Neonatal Health Care Committee of Chinese Maternal and Child Health Association

Author information +

History +

Abstract

Neonates, particularly preterm infants, are a susceptible population to respiratory viral infections. Currently, aside from influenza, there are no antiviral medications specifically approved for the treatment of respiratory viral infections in neonates; therefore, prevention of these viral infections is particularly crucial for neonates. The Neonatal Health Care Committee of Chinese Maternal and Child Health Association, based on domestic and international clinical evidence and combined with clinical practice experience, and after thorough discussion by relevant experts, has developed eight expert recommendations. These include preventive strategies against influenza virus, respiratory syncytial virus, and severe acute respiratory syndrome coronavirus 2 infections, intended for reference in clinical practice.

Key words

Respiratory viral infection / Prevention / Expert recommendation / Neonate

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Neonatal Health Care Committee of Chinese Maternal and Child Health Association. Expert recommendations for the prevention of common respiratory viral infections in neonates[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(8): 789-794 https://doi.org/10.7499/j.issn.1008-8830.2405078

References

1 张智芳, 王晓欢, 梁小洁, 等. 流行性感冒[J]. 中国人兽共患病学报, 2020, 36(7): 593-598. DOI: 10.3969/j.issn.1002-2694.2020.00.090.
2 Kimberlin DW, Barnett ED, Lynfield R, et al. Human Papillomaviruses[M]//Kimberlin DW, Barnett ED, Lynfield R, et al. Red Book (2021): Report of the Committee on Infectious Diseases. Itasca: American Academy of Pediatrics, 2021: 447.
3 Ip DKM, Lau LLH, Chan KH, et al. The dynamic relationship between clinical symptomatology and viral shedding in naturally acquired seasonal and pandemic influenza virus infections[J]. Clin Infect Dis, 2016, 62(4): 431-437. PMID: 26518469. PMCID: PMC4725380. DOI: 10.1093/cid/civ909.
4 Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians[C]. [2021-08-18]. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.
5 中华人民共和国国家卫生健康委员会, 国家中医药管理局. 流行性感冒诊疗方案（2020年版）[J]. 中华临床感染病杂志, 2020, 13(6): 401-405. DOI: 10.3760/cma.j.issn.1674-2397.2020.06.001.
6 马超, 安志杰, 曾玫, 等. 《国家免疫规划疫苗儿童免疫程序及说明（2021年版）》要点解析[J]. 中国疫苗和免疫, 2021, 27(3): 235-241. DOI: 10.19914/j.CJVI.2021041.
7 黄勋, 冯录召, 杜小幸, 等. 中国医疗机构工作人员流感疫苗预防接种指南[J]. 中国感染控制杂志, 2023, 22(8): 871-885. DOI: 10.12138/j.issn.1671-9638.20233814.
8 中国疾病预防控制中心. 中国流感疫苗预防接种技术指南（2022—2023）[J]. 中国病毒病杂志, 2023, 13(1): 1-19. DOI: 10.16505/j.2095-0136.2023.0020.
9 Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2022-2023[J]. Pediatrics, 2022, 150(4): e2022059274. PMID: 36065749. DOI: 10.1542/peds.2022-059274.
10 杨黎琳, 陈健君, 李仪, 等. 我国医务人员流行性感冒疫苗接种意愿的Meta分析[J]. 预防医学, 2024, 36(2): 109-114. DOI: 10.19485/j.cnki.issn2096-5087.2024.02.005.
11 随海田, 杨中楠, 苏锦锋, 等. 中国部分非国家免疫规划疫苗国内外接种现状及免疫策略[J]. 公共卫生与预防医学, 2022, 33(5): 7-12. DOI: 10.3969/j.issn.1006-2483.2022.05.002.
12 Bianchi FP, Stefanizzi P, Cuscianna E, et al. Effectiveness of on-site influenza vaccination strategy in Italian healthcare workers: a systematic review and statistical analysis[J]. Expert Rev Vaccines, 2023, 22(1): 17-24. PMID: 36409195. DOI: 10.1080/14760584.2023.2149500.
13 ACOG Committee opinion No. 741: maternal immunization[J]. Obstet Gynecol, 2018, 131(6): e214-e217. PMID: 29794683. DOI: 10.1097/AOG.0000000000002662.
14 中华医学会围产医学分会, 《中华围产医学杂志》编辑委员会. 孕产妇流感防治专家共识[J]. 中华围产医学杂志, 2019, 22(2): 73-78. DOI: 10.3760/cma.j.issn.1007-9408.2019.02.001.
15 Wentges-van Holthe N, van Eijkeren M, van der Laan JW. Oseltamivir and breastfeeding[J]. Int J Infect Dis, 2008, 12(4): 451. PMID: 18243025. DOI: 10.1016/j.ijid.2007.11.009.
16 Fodor E, Nagy RN, Nógrádi A, et al. An observational study on the pharmacokinetics of oseltamivir in lactating influenza patients[J]. Clin Pharmacol Ther, 2024, 115(2): 318-323. PMID: 37975276. DOI: 10.1002/cpt.3107.
17 National Institute of Child Health and Human Development. Drugs and lactation database (LactMed?)[EB/OL]. [2024-02-15]. https://www.ncbi.nlm.nih.gov/books/NBK501922/.
18 Centers for Disease Control and Prevention. Considerations regarding 2009 H1N1 in intrapartum and postpartum hospital settings[EB/OL]. [2022-04-11]. https://portal.ilca.org/files/in_the_news/Webinars2009/H1N1_December_1_Webinar.pdf.
19 国家呼吸系统疾病临床医学研究中心, 中华医学会儿科学分会呼吸学组. 儿童流感诊断与治疗专家共识（2020年版）[J]. 中华实用儿科临床杂志, 2020, 35(17): 1281-1288. DOI: 10.3760/cma.j.cn101070-20200224-00240.
20 Butler J, Gunnarsson R, Traves A, et al. Severe respiratory syncytial virus infection in hospitalized children less than 3 years of age in a temperate and tropical climate[J]. Pediatr Infect Dis J, 2019, 38(1): 6-11. PMID: 30531526. DOI: 10.1097/INF.0000000000002026.
21 O'Brien S, Borland ML, Cotterell E, et al. Australasian bronchiolitis guideline[J]. J Paediatr Child Health, 2019, 55(1): 42-53. PMID: 30009459. DOI: 10.1111/jpc.14104.
22 Stein RT, Bont LJ, Zar H, et al. Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis[J]. Pediatr Pulmonol, 2017, 52(4): 556-569. PMID: 27740723. PMCID: PMC5396299. DOI: 10.1002/ppul.23570.
23 中华人民共和国国家卫生健康委员会. 医院隔离技术标准WS/T 311-2023[J]. 中国感染控制杂志, 2023, 22(11): 1398-1410. DOI: 10.12138/j.issn.1671-9638.20233818.
24 Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants[J]. N Engl J Med, 2023, 388(16): 1451-1464. PMID: 37018474. DOI: 10.1056/NEJMoa2216480.
25 刘斯宇, 王富珍, Fleming-DutraKE, 等. 美国关于妊娠期间使用呼吸道合胞病毒疫苗预防婴儿呼吸道合胞病毒相关下呼吸道疾病的建议[J]. 中国疫苗和免疫, 2024, 30(3): 377-382. DOI: 10.19914/j.CJVI.2024061.
26 American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection[J]. Pediatrics, 2014, 134(2): e620-e638. PMID: 25070304. DOI: 10.1542/peds.2014-1666.
27 Anderson EJ, Carosone-Link P, Yogev R, et al. Effectiveness of palivizumab in high-risk infants and children: a propensity score weighted regression analysis[J]. Pediatr Infect Dis J, 2017, 36(8): 699-704. PMID: 28709160. PMCID: PMC5516669. DOI: 10.1097/INF.0000000000001533.
28 Griffin MP, Yuan Y, Takas T. Single-dose nirsevimab for prevention of RSV in preterm infants[J]. N Engl J Med, 2020, 383(5): 415-425. PMID: 32726528. DOI: 10.1056/NEJMoa1913556.
29 Robbie GJ, Criste R, Dall'acqua WF, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults[J]. Antimicrob Agents Chemother, 2013, 57(12): 6147-6153. PMID: 24080653. PMCID: PMC3837853. DOI: 10.1128/AAC.01285-13.
30 Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants[J]. N Engl J Med, 2022, 386(9): 837-846. PMID: 35235726. DOI: 10.1056/NEJMoa2110275.
31 Domachowske J, Madhi SA, Sim?es EAF, et al. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity[J]. N Engl J Med, 2022, 386(9): 892-894. PMID: 35235733. DOI: 10.1056/NEJMc2112186.
32 Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices: United States, 2023[J]. MMWR Morb Mortal Wkly Rep, 2023, 72(34): 920-925. PMID: 37616235. PMCID: PMC10468217. DOI: 10.15585/mmwr.mm7234a4.
33 Sim?es EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials[J]. Lancet Child Adolesc Health, 2023, 7(3): 180-189. PMID: 36634694. PMCID: PMC9940918. DOI: 10.1016/S2352-4642(22)00321-2.
34 Zhu Q, McLellan JS, Kallewaard NL, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants[J]. Sci Transl Med, 2017, 9(388): eaaj1928. PMID: 28469033. DOI: 10.1126/scitranslmed.aaj1928.
35 Raschetti R, Vivanti AJ, Vauloup-Fellous C, et al. Synthesis and systematic review of reported neonatal SARS-CoV-2 infections[J]. Nat Commun, 2020, 11(1): 5164. PMID: 33060565. PMCID: PMC7566441. DOI: 10.1038/s41467-020-18982-9.
36 Chen ZM, Fu JF, Shu Q, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus[J]. World J Pediatr, 2020, 16(3): 240-246. PMID: 32026148. PMCID: PMC7091166. DOI: 10.1007/s12519-020-00345-5.
37 García H, Allende-López A, Morales-Ruíz P, et al. COVID-19 in neonates with positive RT-PCR test. Systematic review[J]. Arch Med Res, 2022, 53(3): 252-262. PMID: 35321802. PMCID: PMC8919773. DOI: 10.1016/j.arcmed.2022.03.001.
38 Yung CF, Kam KQ, Wong MSY, et al. Environment and personal protective equipment tests for SARS-CoV-2 in the isolation room of an infant with infection[J]. Ann Intern Med, 2020, 173(3): 240-242. PMID: 32236490. PMCID: PMC7133054. DOI: 10.7326/M20-0942.
39 Yeo KT, Biswas A, Ying Ho SK, et al. Guidance for the clinical management of infants born to mothers with suspected/confirmed COVID-19 in Singapore[J]. Singapore Med J, 2022, 63(9): 489-496. PMID: 33866749. PMCID: PMC9678132. DOI: 10.11622/smedj.2021045.
40 Harada YU, Amo H, Ono T, et al. Inactivation of SARS-CoV-2 by commercially available disinfectants and cleaners[J]. Biocontrol Sci, 2022, 27(4): 223-228. PMID: 36567119. DOI: 10.4265/bio.27.223.
41 海峡两岸医药卫生交流协会新生儿学专业委员会新生儿循证医学学组. 新生儿新型冠状病毒感染的诊断与治疗专家共识[J]. 中华全科医学, 2023, 21(5): 726-731. DOI: 10.16766/j.cnki.issn.1674-4152.002969.
42 中国当代儿科杂志编辑委员会围产新生儿新型冠状病毒感染防控管理预案工作组. 围产新生儿新型冠状病毒感染防控管理预案（第三版）[J]. 中国当代儿科杂志, 2023, 25(1): 1-4. PMID: 36655656. PMCID: PMC9893817. DOI: 10.7499/j.issn.1008-8830.2212074.